Abstract 2224: Re-engineering of the duocarmycin structural architecture enables tumour-selective CYP2W1-mediated drug activation in human colon cancer xenografts
Pors, Klaus, Travica, Sandra, Loadman, Paul M., Shnyder, Steven D., Sutherland, Mark, Sheldrake, Helen M., Searcey, Mark, Johansson, Inger, Mkrtchian, Souren, IngelmanSundberg, Magnus, Patterson, Laurence H.
Published in Cancer research (Chicago, Ill.) (15.04.2013)
Published in Cancer research (Chicago, Ill.) (15.04.2013)
Get full text
Journal Article